Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ucb ADR
(OP:
UCBJY
)
90.03
+0.45 (+0.50%)
Streaming Delayed Price
Updated: 3:50 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Ucb ADR
There's Optimism Around Longboard Pharmaceuticals' Anti-Seizure Candidate: Analyst Boosts Price Target
January 02, 2024
Tuesday, Longboard Pharmaceuticals Inc (NASDAQ: LBPH) released topline data from the PACIFIC Phase 1b/2a study evaluating bexicaserin (LP352) for seizures associated with a broad range of...
Via
Benzinga
Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst
September 28, 2023
Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), a recent reverse merger with the old Magenta Therapeutics.
Via
Benzinga
Skin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst Asserts
August 31, 2023
Needham initiated coverage on MoonLake Immunotherapeutics (NASDAQ: MLTX) with a Buy rating and
Via
Benzinga
FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults
June 27, 2023
The FDA approved UCB SA's (OTC: UCBJF) (OTC: UCBJY) Rystiggo (rozanolixizumab-noli) for generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or...
Via
Benzinga
Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path
February 14, 2023
Via
Benzinga
UCB's Rare Childhood Epilepsy Drug Scores FDA Approval
March 28, 2022
Via
Benzinga
The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More
May 30, 2022
Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstanding the week's strength, the sector has been one of the worst performers for...
Via
Benzinga
Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane
February 08, 2022
Biogen Inc (NASDAQ: BIIB) and Xbrane Biopharma AB have
Via
Benzinga
The Week Ahead In Biotech (Jan. 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, & More
January 23, 2022
Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the frenetic pace of the week that...
Via
Talk Markets
The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More
January 23, 2022
Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the...
Via
Benzinga
UCB's Bispecific Marks Phase 3 Win For Second Psoriatic Arthritis Study
January 21, 2022
UCB SA (OTC: UCBJF) posted topline results from the Phase 3 BE COMPLETE study evaluating Bimzelx (bimekizumab) for active psoriatic arthritis patients who were...
Via
Benzinga
ZGNX Stock: The $1.9B UCB Deal That Has Zogenix Shares Zooming Higher Today
January 19, 2022
Zogenix (ZGNX) stock is skyrocketing on Wednesday following news that UCB (UCBJY) intends to acquire the company in a $1.9 billion deal.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 2, 2021
September 02, 2021
Upgrades For Okta Inc (NASDAQ:
Via
Benzinga
UCB Gets EU Approval For Bimekizumab In Psoriasis
August 25, 2021
The European Commission has cleared UCB's (OTC: UCBJF) Bimzelx (bimekizumab) for moderate to severe plaque psoriasis in adults. UCB's confidence lies in...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 23, 2021
August 23, 2021
Upgrades JP Morgan upgraded the previous rating for Pearson PLC (NYSE:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 23, 2021
July 23, 2021
Upgrades Craig-Hallum upgraded the previous rating for Lindblad Expeditions Holdings Inc (NAS...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 9, 2021
July 09, 2021
h2>Upgrades According to HSBC, the prior rating for NIO Inc (NYSE:
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.